Skip to main content
  • 7 Nikola Pašić Sq., 4th Fl., 11000 Belgrade
  • info@smj.rs

logo LKS

Original article

Anamu, moringa, spirulina, and chlorella: contribution to the quality of life of oncology patients – results of the postmarketing prospective study performed in Serbia in 2021 – 2022

Anabely Estevez Garcia1, Vladimir Kovčin2, Aliuska Venegas Godinez1
  • International Health Center, La Pradera, Cuba
  • Oncomed-System, Belgrade, Serbia

ABSTRACT

Introduction: The quality of life is one of the priority goals in the treatment of oncology patients. In addition to conventional therapies, symptomatic and supportive treatments are valuable for the final treatment outcome. Many such patients resort to alternative methods, such as herbal therapy.

Study aim: This prospective study aimed to assess the effect of the plants: anamu, moringa, spirulina, and chlorella, which are routinely used in Cuba, on the quality of life of oncology patients.

Materials and methods: Forty-six patients with various stage four malignant tumors were examined. Of the 46 patients, 26 were on chemotherapy, while 18 were on symptomatic and supportive therapy. The patients used extracts of the aforementioned plants orally, for three months. With prior consent and authorization, the standard EORTC QLQ-C30 questionnaire, written in the patients’ native language, was used to assess quality of life, before and after three months of use.

Results: According to patient ratings, overall assessment of patient general health status and quality of life showed significant improvement after three months of use of the extracts, as compared to the beginning of application. According to the questionnaire, all five parameters improved on the functional scale, (p < 0.001), and the scores on the symptoms scale also improved (fatigue, p = 0.015; pain, p = 0 ,044). Women achieved better physical functionality and significant loss of fatigue and pain, while cognitive functionality improved in men. Emotional functionality improved in the subgroup of patients who were receiving chemotherapy, while in those who had previously received chemotherapy, there were significant differences in the symptoms scale score regarding loss of appetite and constipation – symptoms that resolved after three months of product use, thus equating the subgroups in terms of the reduction of these symptoms. In other functional parameters, statistically significant differences were also obtained for all patients.

Conclusion: The improvement in the quality of life and functionality of patients, as well as the reduction in symptoms, whether the patients received chemotherapy or not, was statistically significant.


INTRODUCTION

Herbal medicine (phytotherapy) is the oldest form of treatment that uses plants and plant derivatives due to their medicinal properties [1].

The use of plants was the basis for the development of modern medicine, and in some rural and indigenous areas, they represent the only available means of treatment, due to the lack of medical facilities and resources for the application of modern medicine. In many communities, folk medicine has not yet disappeared. In addition to plant species that thrive in certain habitats, today there are opportunities to use plant species that do not grow in the area we live in. Therefore, we benefit from the use of medicinal plants (i.e., medicinal herbs), not only in the treatment of diseases, but also in the prevention of diseases and in nutrition [2].

In the 1990s, Professor Rosenberg, from the Department of Public Health at Harvard Medical School, citing the importance of integrative medicine, published two reports showing that 45% of American patients, after visiting their doctor, seek help from professionals in the field of what is often referred to as ‘alternative medicine’ [3], as an approach that is complementary to official medicine.

Integrative medicine represents a medical doctrine based on Hippocrates’ vision of the ‘art of healing’, which emphasizes the importance of treating the whole patient, i.e., applying a holistic approach to a person with health problems [4],[5]. The integrative model combines the knowledge of Western, science and technology based medicine (founded on scientific evidence), with certain therapeutic resources of what is known as ‘complementary medicine’, which includes the use of medicinal plants, as indicated by a professional, i.e., phytotherapy.

Integrative medicine is also very useful in the treatment of malignant diseases, when, at the same time, we want to preserve the patient’s quality of life [6],[7],[8]. Also, by applying the principles of integrative medicine, the fundamental role of appropriate nutrition in improving the general health status of patients is emphasized, which implies the creation of an individual nutrition program tailored to the patient’s disease [9].

Although, thus far, there is not enough evidence on the effectiveness of phytotherapy as the therapy of choice in the treatment of malignancies, there are indications that it can improve the quality of life. Phytotherapy can help patients with malignant diseases to cope with the side effects of therapy, as well as with some symptoms of malignant diseases. For example, the use of natural plant components in therapeutic concentrations, by adding orthomolecular supplementation, can help reduce the intake of traditional drugs (analgesics, anti-inflammatory drugs, anti-anxiety drugs, etc.) [6],[7],[8].

In Cuba, natural medicine uses phytotherapy as supplementary to conventional therapy in the treatment of chronic diseases, such as malignant diseases. Phytotherapy, as part of medical practice, uses professional experience to alleviate the symptoms of disease and the toxicity of conventional therapies. In a personalized approach to the treatment of patients with malignant tumors, standard medical practice, along with supportive therapy, leads to an improvement in the quality of life of patients, as well as an increase in the chances of recovery [10].

Phytotherapy, as a form of alternative therapy, helps to improve the function of the patient’s immune system by reducing oxidative stress, which slows down the progression of the disease, improves nutritional status, and promotes better tolerance to conventional therapies [11].

Among the plants that are used the most in Cuba for alternative cancer treatment, and which have been studied more closely, anamu, moringa, spirulina and chlorella stand out.

Anamu

Anamu or Petiveria alliacea L. (Phytolaccaceae) is an indigenous plant of the Amazon jungle and can also grow in areas such as tropical and Central America, the Caribbean and the southeastern part of the United States of America. It represents one of the plants with the greatest pharmacological potential in the world, as demonstrated by the fact that it was selected, at the University of Illinois, among 14,000 plant extracts, as one of 34 candidates with antitumor potential.Due to its numerous medicinal properties, it was studied in detail by the Pharmaceutical Laboratory in Cuba, where it was clarified that medicinal plants with therapeutic immunostimulating effects are not common in the plant kingdom. Anamu grows in abundance, both in the desert and in the cultivated areas of Cuba. It has proven effects in stimulating immune system cell response, which has justified the production of tablets made from the plant, and the registration of this supplement as a herbal immunostimulant, in accordance with the requirements of the Cuban regulatory authorities for the human use of drugs. The above-mentioned tablets contain a dose of powder made from the leaves and stems of the plant [10].

According to research conducted in Cuba by a team of scientists led by Dr. Zoe Lemus Rodríguez, anamu (the whole plant) contains numerous active ingredients, including the following: alkaloids (allantoin, N-methyl-4-trans methoxy proline); steroids (beta-sitosterol); triterpenes (isobornyl, isobornyl acetate, isobornyl cinnamate, alpha-friedelinol); sulfur derivatives (benzyl-2-hydroxy-5-ethyl-trisulfide, dibenzyl trisulfide); flavonoids (astilbin, gelatin, leridal, leridol, leridol-5-methyl-ether, myricitrin); inorganic compounds (potassium nitrate); lipids (lignoceric acid, lignoceryl lignocerate, linoleic acid, nonadecanoic acid, oleic acid, palmitic acid, stearic acid); benzene derivatives (benzaldehyde, benzoic acid); alkanes (lignoceryl alcohol); carbohydrates (pinitol). In particular, properties such as immunostimulation are attributed to tannins, polyphenols and benzyl-2-hydroxy-5-cetyl-trisulfide, which are found in the leaves and young stems of the plant [10],[11].

At the National Center for Scientific Research of Cuba, a study was conducted on anamu plant extracts which revealed the presence of elements such as selenium (Se), zinc (Zn), copper (Cu), iron (Fe) and magnesium (Mg), which affect the immune system [10].

In 1993, Jovićević demonstrated the inhibitory effect of anamu on tumor proliferation, especially in leukemia cell lines, without endangering healthy tissue [12].

Marini et al. described the effect of anamu plant extracts on the production of cytokines, such as interleukin-2 and interleukin-4, as well as on increasing the cytotoxic activity of natural killer cells (NK cells) [13].

In 1997, Williams reported that anamu increased the activity of the thymus and white blood cells. Other authors pointed out that the immunomodulatory effect is due to a significant increase in the phagocytic index of granulocytes in humans [14].

Recently, a test with an aqueous extract of this plant confirmed that it stimulates the production of lymphocytes and interleukin-2 in rats. A year later, in an experiment with mice, it was shown that the extract of anamu increases the activity of NK lymphocytes by 100%, and that it stimulates the production of interferon, interleukin-2 and interleukin-4 [14],[15],[16].

The latest findings on the action of tyrosine kinase inhibitors and molecular targets in oncology are currently linked to the investigation of the possibility of obtaining an antitumor pharmacological agent from this plant [17].

Moringa

Moringa (Moringa oleifera) is an evergreen tree and the best known and most widespread species in the Moringaceae family. Moringa leaves contain b-carotene, vitamin C, flavonoids, phenolic compounds, fatty acids, such as omega-3 and omega-6 fatty acids, as well as calcium and potassium. Its seeds have a high content of carbohydrates, lipids and proteins, which make up from 33% to 60% of its dry matter. This species is widely used for its preventive properties in chronic diseases (including antispasmodic, antidiuretic, antihypertensive, antiulcer, anticancerogenic, antidiabetic, antimicrobial, and antihypercholesterolemic properties) [18],[19],[20],[21],[22].

Protein isolates from this plant are used as food supplements and have the potential to generate bioactive peptides in vitro, by proteolysis or digestion. Peptides can be produced naturally by the gastrointestinal digestion process, but they can also be obtained in vitro, using proteolytic enzymes. The biofunctional properties of these peptides are related to regulatory functions in the cardiovascular, digestive, immune and nervous systems, depending on the composition and structure of amino acids. Moringa’s nutritional properties include antioxidant activity in the suppression of lipid peroxidation, antihypertensive function associated with the inhibition of angiotensin-converting enzyme (ACE), antidiabetic properties associated with amylase activity, anti-inflammatory properties, as well as the function of slowing cell aging, antimicrobial properties, and other [23],[24],[25],[26],[27].

Moringa oleifera contains a significant quantity of important phytochemicals, such as phenols, flavonoids, alkaloids, vitamins, glycosides, sterols, minerals and amino acids, in its seeds, leaves and fruit. Moringa seeds have been shown to have diuretic as well as antitumorous and antimicrobial properties. In 2005, a study was published that provided information on the cytotoxic effect of the ethanolic root extract of the Moringa oleifera plant on leukemia and melanoma cell lines. MCF7 is an estrogen-positive breast cancer cell line commonly used as an in vitro model in breast cancer therapeutic research [18],[28],[29],[30],[31],[32].

Moringa seeds contain dimeric cationic proteins (13-kDa), which is why they have coagulant and antimicrobial properties, and can be used for decontamination and treatment of turbid water. Moringa seeds contain 19% - 47% of essential oils, which are an excellent nutritional supplement. The seed oil is used not only as a vegetable oil for cooking, resistant to oxidative degradation, but also for the treatment of various nutritional intoxications [18],[33].

Spirulina and chlorella

Spirulina platensis (Sp) is a spiral-filamentous alga from the family of multicellular and photosynthetic cyanobacteria (blue-green algae) belonging to the class Cyanophyceae, the family Oscillatoriaceae. This cyanobacterium is cultivated worldwide and used as a primary dietary supplement. It contains a wide range of prophylactic and healing nutrients – vitamins, minerals, proteins, linoleic acid, b-carotene, as well as unexplored bioactive compounds. In addition to nutritional benefits, spirulina has other properties, such as antibacterial, antifungal, antiviral, anticancerous, anti-inflammatory and antioxidant properties, and is also used as a nutritional supplement in aquaculture and poultry farming [34].

Chlorella vulgaris (Cv) is a freshwater, green, unicellular microalga, belonging to the phylum Chlorophyta and recognized worldwide as a functional food product. It is rich in proteins, lipids, carotenoids, vitamins and minerals and is considered a valuable source of protein among potential food sources. It contains both omega-3 and omega-6 fatty acids, carbohydrates, cellulose, essential amino acids, carotenes and vitamin A. In addition, chlorella is used as a protein supplement for human consumption and as an alternative antibiotic in livestock production. Chlorella has also been confirmed to have immunomodulatory activity in chickens, improving growth performance and egg quality [35].

Among its active ingredients, Spirulina platensis contains minerals, vitamins, essential amino acids and proteins, as well as beta-carotene, tocopherols and phenolic acids, which have shown a high level of anti-inflammatory and antioxidant properties. This is why it is used as a supplement in human nutrition, as well as in the nutrition of many animal species, such as birds and fish. In addition, Spirulina platensis also contains a highly active ingredient, c-phycocyanin, which exhibits anti-inflammatory, immunomodulatory, hepatoprotective, nephroprotective, neuroprotective, antidiabetic, antigenotoxic, antihypertensive and anticancerous effects [34].

Spirulina is also rich in tetrapyrroles, which are directly linked to the bilirubin molecule, a powerful antioxidant and antiproliferative agent. The potential anticancerous effects of tetrapyrrole obtained from S. platensis are being investigated in pancreatic cancer. The antiproliferative effects of S. platensis and its tetrapyrrole components (phycocyanin (PCB) and chlorophyllin, a molecule that is a substitute for chlorophyll A) showed some activity in human pancreatic cancer cell lines and in nude mice with xenotransplanted cells [34].

STUDY AIM

The aim of the study was to assess the effect of the application of plant extracts from Cuba: anamu, moringa, spirulina, and chlorella, as dietary supplements, on the quality of life of oncology patients, during and after the application of oncology therapy.

MATERIALS AND METHODS

Fourty-six patients were included in the post-marketing prospective non-randomized study. Patients who agreed to fill out a questionnaire on quality of life before using herbal preparations were included. The extracts were previously registered in Serbia as a dietary supplement, and the patients received them as a donation from Cuban doctors. The study included patients suffering from various malignant tumors (nine patients with breast cancer, seven with lung cancer, six with colon cancer, five with prostate cancer, four with head and neck cancer, three with lymphoma, two with cervical cancer and one with ovarian cancer, two with stomach cancer, two with urinary tract cancer, two with brain cancer, two with soft tissue sarcoma, and one with pancreatic cancer). Of these patients, 20 were men and 26 were women, aged from 30 to 87 years, with the average age of 60. The patients underwent regular oncological follow-up, every three months, with their oncologist, in different oncological centers in Serbia.

There were 28 patients who received chemotherapy (10 men and 18 women), as well as 18 patients without chemotherapy (10 men and 8 women), (Table 1). The patients were in stage four of the disease.

Table 1. Respondent characteristics

anamu 01

With the approval of the European Organization for Research and Treatment of Cancer (EORTC), (Request ID: 89647), the standard EORTC QLQ-C30 questionnaire with 30 questions was used to assess quality of life [36]. The patients gave verbal consent and voluntarily filled out the questionnaire before starting to use the herbal preparations and after three months of use.

Preparations of herbal extracts of anamu, moringa and spirulina, plus chlorella, are individually encapsulated in three gelatin capsules of 400 mg, 500 mg and 500 mg, with a proportion of 80% spirulina and 20% chlorella. All patients confirmed compliance with the use of the preparation at home, after three months.

In keeping with the prescription for the preparation, during the first week the therapy was taken in the form of one capsule of each dietary supplement, in the morning only. In the second week, one capsule of each dietary supplement, in the morning and in the afternoon, was taken. In the third week, one capsule of each dietary supplement was taken, morning, afternoon and evening. From the fourth week onwards, patients took two capsules of each dietary supplement, in the morning, in the afternoon, and in the evening. Anamu was taken 15 minutes before a meal, and moringa and spirulina, during or after a meal.

The EORTC scoring system [37] and standard statistical methods – Wilcoxon test, chi-square test, and Fisher’s exact test, were used to process the obtained results, with the aim of determining a statistical significance, before and after the application of the preparation.

According to the scoring system, the questionnaire is divided into five functional scales, three symptoms scales, a global health status/quality of life scale, and six individual items (Table 2).

Table 2. EORTC QLQ-30 scoring system, Version 3.0

anamu 02

Higher score values on the functional scale, from 1 to 5, represent a high/healthier level of functioning. A higher score on the general health status scale, from 1 to 7, represents a better quality of life. On the other hand, a higher score on the symptoms scale, from 1 to 5, represents a more intense level of symptoms/problems.

RESULTS

The examined groups, according to gender and application of chemotherapy, did not differ in their characteristics, except for the fact that, before the application of therapy, women had slightly worse cognitive functions on the functional scale (result: 64.1 ± 31.51 vs. 44.17 ± 28.24, p = 0.027).

The assessment of patient global health status and quality of life, according to the results obtained, improved statistically significantly after three months of using the preparation (Graph 1).

anamu 03

Figure 1. Global health status and quality of life score, before and after the use of the preparation, in the entire group of respondents (N46) and in the subgroups, during chemotherapy (HT) (N28) and without ht (N18)

On the functional scale, statistically significant improvement was recorded for five parameters (Graph 2).

anamu 04

Figure 2. Functional scale score: physical (PF2), role (RF2), emotional (EF), cognitive (CF), and social (SF), before and after the use of the preparation (the whole group), (N46)

On the symptoms scale, a statistically significant improvement was noted in all parameters except for dyspnea and financial difficulties (Graph 3).

anamu 05

Figure 3. Symptoms scale: fatigue (F), nausea and vomiting (NV), pain (P), dyspnea (DY), sleeplessness (SL), loss of appetite (AP), constipation (CO), diarrhea (DI), and financial difficulties (FI), in the whole group (N46)

After using the preparation, women statistically achieved a slightly better result on the functional scale of physical functioning, while men achieved a slightly better result on the scale of cognitive functioning (Graph 4). On the symptoms scale, women had a more significant improvement regarding the sensation of fatigue and pain than men (Graph 5). There is a greater difference in the absolute score for fatigue, before and after the application of the preparation in women, which is also statistically significant (106.7 ± 15.88 vs. 97.44 ± 19.7, before, and 41.67 ± 17.24 vs. 27.78 ± 17, after).

anamu 06

Figure 4. lFunctional scale: physical functioning (PF2) and cognitive functioning (CF), Differences by sex, before and after therapy

anamu 07

Figure 5. lSymptoms scale: fatigue (FA), pain (PA), differences by sex, before and after thera

In the subgroup of patients who received chemotherapy, a statistically significant improvement in emotional functioning was achieved on the functional scale after the application of phytotherapy, and it was more significant than in the subgroup that did not receive chemotherapy (Graph 6). For other functionality parameters, for which a statistically significant difference was registered. (Graph 2), there was no difference between those patients who received chemotherapy and those who did not.

anamu 08

Figure 6. Functional scale: emotional (EF), in the group of patients who were on chemotherapy (N28) and in the group of patients who did not receive chemotherapy (N18) during the use of the preparation

In patients who received chemotherapy before starting on the preparation, there was a significant difference in the symptoms scale regarding the loss of appetite and constipation. This difference disappeared after three months of drug use and the subgroups were equal in terms of the reduction of these symptoms (Graph 7).

anamu 09

Figure 7. Symptoms scale scoring, loss of appetite (AP) and constipation (CO), in patients during chemotherapy (N28) and in patients who were not on chemotherapy (N18) during the use of the preparation

DISCUSSION

The study aimed to analyze the quality of life of patients with various malignant tumors, before and three months after the application of extracts from the plants anamu, moringa, spirulina and chlorella.

The most important results of this study show that, after three months of using the preparation, all functional parameters (physical, daily functioning, emotional, cognitive, and social functioning) improved significantly in patients, regardless of whether they received chemotherapy or not, and without gender differences.

According to trend research, more than 65% – 75% of patients with malignant diseases used some kind of complementary medicine [38], and according to World Health Organization data, this number is as high as 80% [39]. This is suggested to patients by family members, friends or someone who is already being treated for a malignancy.

In Serbia, the application of phytotherapy is still at a modest level. Serbian authors have shown that almost a third of patients believe that they can cure their disease with these methods, while the majority expect to achieve better treatment results with conventional methods than with alternative ones [40].

Complementary and alternative medicine are recognized treatment methods in many countries. These treatment methods include phytotherapy, which usually accounts for around 50% [41]. In the period between 1940 and 2014, more than half of the anticancer drugs that entered routine use were obtained from plants [39],[42].

Side effects of cytotoxic drugs significantly impair the quality of life during treatment. Among them, the most common are nausea and vomiting, loss of appetite, and weight loss [43]. In our study, patients receiving chemotherapy had significantly higher scores on the appetite loss scale than those not receiving chemotherapy. After three months of phytotherapy, there was a statistically significant reduction in 7 out of 9 symptoms on the symptoms scale, such as fatigue, nausea and vomiting, pain, dyspnea, insomnia, loss of appetite and constipation. The most significant improvement was achieved for loss of appetite and constipation (Graph 7).

Minimal differences and slightly better effects in women, on the physical functionality scale, as well as for pain and fatigue, on the symptoms scale, can be explained by the greater general vulnerability of the female population.

Improvement in emotional functionality in chemotherapy patients is particularly significant, as it boosts morale and the desire to fight the disease.

Analysis of the symptoms scale before the use of herbal preparations shows that there is a significant difference, in terms of more pronounced symptomatology, in patients who received chemotherapy, as compared to those who did not, which was to be expected. After three months of preparation use, these differences among patients disappeared, with a significant improvement and reduction in 7 out of 9 of the assessed symptoms.

The idea of herbal medicine complementing conventional commercial treatment is becoming increasingly popular, as it could overcome financial difficulties as well as health problems caused by modern treatments. Herbal medicines would be cheaper, making them more accessible to people in rural and poor areas. These drugs would have fewer side effects and therefore improve the patient’s quality of life during treatment [44]. The combination of several plant components should have a greater potential and more effects on the disease than a single plant, as a consequence of the synergistic effect of its components [45]. There is evidence that numerous active components of various herbal mixtures act on malignant cells and other diseases. In addition, they are suitable for overcoming resistance to therapies because they act on different targets [46].

Although it is known that the combination of chemotherapy drugs and bioactive substances from medicinal plants can have anticancerous effects, while reducing side effects [47], our study could not analyze the possible anticancerous effects of anamu, spirulina, chlorella, and moringa, which have been described in literature dealing with the use of these plants [20],[40], due to the small number of subjects and the heterogeneous group of malignancies that were treated with different methods. The results of this study refer only to anamu, moringa, spirulina and chlorella and cannot be applied to other medicinal plants. According to the World Health Organization, out of 2,500,000 species of plants, 80,000 have therapeutic properties and about 21,000 have the potential to be used as medicinal plants [40].

Given that preparations of plant extracts are registered in Serbia and are available to all oncology patients, they can be used as a supplement in supportive and symptomatic therapy, with the aim of improving the quality of life in patients.

Although the study was conducted on a small number of subjects and is heterogeneous in terms of tumor pathology, it provides information on the effects of Cuban herbal preparations for which there is not much information in medical professional journals. This indicates the need for additional research on a larger number of subjects and in relation to specific tumors.

CONCLUSION

According to the obtained respondent answers, the overall assessment of the global health status and quality of life of the patients showed that they improved significantly, which indicates the benefit of consuming nutritional supplements made from the plants anamu, moringa, spirulina and chlorella, for the quality of life and for reducing the symptoms in oncology patients.

The improvements described are present both in patients with diagnosed disease who did not receive conventional therapy and in patients who received chemotherapy.

  • Conflict of interest:
    None declared.

Informations

Volume 4 No 3

September 2023

Pages 222-237
  • Keywords:
    malignant tumors, quality of life, anamu, chlorella, moringa, spirulina
  • Received:
    17 August 2023
  • Revised:
    01 September 2023
  • Accepted:
    13 September 2023
  • Online first:
    25 September 2023
  • DOI:
  • Cite this article:
    Estevez GA, Kovčin V, Venegas GA. Anamu, moringa, spirulina, and chlorella: Contribution to the quality of life of oncology patients: Results of the postmarketing prospective study performed in Serbia in 2021 - 2022. Serbian Journal of the Medical Chamber. 2023;4(3):222-37. doi: 10.5937/smclk4-46031
Corresponding author

Vladimir Kovčin
Oncomed-System, Belgrade, Serbia
91 Karpoševa Street, 11000 Belgrade, Serbia
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.


  • 1. De la Cruz M, Bandiano J. Libellus de medicinalibus Indorum herbis: manuscrito azteca de 1552. 2. ed. México, D.F: Fondo de Cultura Económica: Instituto Mexicano del Seguro Social; 1991. 2 p.

    2. Figueroa-Hernández JL, Céspedes-Cortés, Figueroa-Espitia JL. Flora Silvestre presente en un nuevo asentamiento urbano en la Delegación de Xochimilco en México, D.F. In: XXVI Congreso Nacional de Farmacología; 2004 Мay 25-28; Morelia, Michoacán, Mexico.

    3. Greenlee H, Balneaves LG, Carlson LE, Cohen M, Deng G, Hershman D, et al. Society for Integrative Oncology. Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. J Natl Cancer Inst Monogr. 2014 Nov;2014(50):346-58. doi: 10.1093/jncimonographs/lgu041. [CROSSREF]

    4. Lianes Barragan P, Fernández Bruno M, Martínez Peralta S. Medicina Integrativa en el paciente oncológico. In: Escobar Álvarez Y, Blasco Cordellat A, Espinosa Arranz J, De las Peñas Bataller R, Del Mar Muñoz Sánchez M, Virizuela Echaburu JA, et al., editors. Manual de Cuidados Continuos de SEOM, 2A Edición. Madrid: Sociedad Española de Oncología Médica (SEOM); 2014. p. 489-97.

    5. Bañuelos MR. Medicina integrativa en el paciente oncológico: Estrategia de la Organización Mundial de la Salud y estado actual. Revista Medica de Homeopatia. 2013;6(3):136-40. doi: 10.1016/j.homeo.2013.10.001. [CROSSREF]

    6. Shike M, Brennan MF. Supportive care of the cancer patient. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice in Oncology. Philadelphia, PA: J.B. Lippincott; 1989. P. 2029-44.

    7. Deng GE, Frenkel M, Cohen L, Cassileth BR, Abrams DI, Capodice JL, et al. Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals. J Soc Integr Oncol. 2009;7(3):85-120. [HTTP]

    8. Thinking About Complementary and Alternative Medicine: A Guide for People with Cancer. National Institutes of Health.

    9. Heber D, Blackburn GL, Go VLW. Introduction: The principles of nutrition oncology. In: Heber D, Blackburn GL, Go VLW. Nutritional Oncology. San Diego, CA: Academic Press; 1999. p. 1-10.

    10. Lemus Rodríguez Z, García Pérez ME, Batista Duharte A, De la Guardia Peña O, Alfonso Castillo A. La tableta de anamú: un medicamento herbario inmunoestimulante. MEDISAN. 2004;8(3).

    11. García Pérez ME, Lemus Rodríguez Z, Hung Arbelo M., Vistel Vigo M. Influence of polyvinylpyrrolidone, microcrystalline cellulose and colloidal silicon dioxide on technological characteristics of a high-dose Petiveria alliacea tablet. Drug Dev. Ind. Pharm. 2017 Dec; 43(12):2011-5. doi: 10.1080/03639045.2017.1359621. [CROSSREF]

    12. Jovicevic L, Troiani MP, Capezzone de Joannon A, Saso L, Mazzanti G, Rossi V. In vitro antiproliferative activity of Petiveria alliacea L. on several t tumor cell lines. Pharmacol Res. 1993;27(S1):105-6. doi: https://doi.org/10.1006/phrs.1993.1087. [CROSSREF]

    13. Marini S, Jovicevic L, Milanese C, Giardina B, Leone MG. Effects of Petiveria alliacea L. on cytokine production and natural killer cell activity. Pharmacol Res. 1993;27(S1):107-8. doi: https://doi.org/10.1006/phrs.1993.1088. [CROSSREF]

    14. Williams LAD, The TL, Gardner MT, Fletcher CK, Naravane A, Gibbs N, et al. Immunomodulatory activities of Petiveria alliacea L. Phytother Res. 1997;11(3):251- 3. doi: 10.1002/(sici)1099-1573(199705)11:33.0.co;2-b. [CROSSREF]

    15. Kubec R, Musah R. Cysteine sulfoxide derivatives in Petiveria alliacea. Phytochemistry. 2001 Nov;58(6):981-5. doi: 10.1016/s0031-9422(01)00304-1. [CROSSREF]

    16. Queiroz ML. Cytokine profile and natural killer cell activity in Listeria monocytogenes infected mice treated orally with Petiveria alliacea extract. Immunopharmacol Immunotoxicol. 2000 Aug;22(3):501-18. doi: 10.3109/08923970009026008. [CROSSREF]

    17. Urueña C, Cifuentes C, Castañeda D, Arango A, Kaur P, Asea A, et al. Petiveria alliacea extracts multiple mechanisms to inhibit growth of human and mouse ttumoral cells. BMC Complement Altern Med. 2008;8(60). doi: 10.1186/1472-6882-8-60. [CROSSREF]

    18. Anwar F, Latif S, Ashraf M, Gilani AH. Moringa Oleifera: a food plant with multiple medicinal uses. Phytother Res. 2007 Jan;21(1):17-25. doi: 10.1002/ ptr.2023. [CROSSREF]

    19. Kasolo JN, Bimenya GS, Ojok L, Ochieng J, Ogwal-Okeng JW. Phytochemicals and uses of Moringa Oleifera leaves in Ugandan rural communities. J Med Plants Res. 2010;4(9):753-7.

    20. Vats S, Grupta T. Evaluation of bioactive compounds and antioxidant potential of hydroethanolic extract of Moringa Oleifera Lam from Rajasthan, India. Physiol Mol Biol Plants. 2017 Jan;23(1):239-48. doi: 10.1007/s12298- 016-0407-6. [CROSSREF]

    21. Mehta S, Rai PK, Rai NK, Rai AK, Bicanic D, Watal G. Role of spectral studies in detection of antibacterial phytoelements and phytochemicals of Moringa Oleifera. Food Biophys. 2011 Jun;6(4):497-502. doi: 10.1007/s11483-011-9231-2. [CROSSREF]

    22. Jung IL. Soluble extract from Moringa Oleifera leaves with a new anticancer activity. PLoS One. 2014 Apr;9(4):e95492. doi:10.1371/journal.pone.0095492. [CROSSREF]

    23. Kitts DD, Weiler K. Bioactive proteins and peptides from food sources. Applications of bioprocesses used in isolation and recovery. Curr Pharm Des. 2003;9(16):1309-23. doi: 10.2174/1381612033454883. [CROSSREF]

    24. Lopez-Sanchez J, Ponce-Alquicira E, Pedroza-Islas R, de la Peña Diaz A, Soriano-Santos J. Effects of heat and pH treatments and in vitro digestion on the biological activity of protein hydrolysates of Amaranthus hypochondriacus L. grain. J Food Sci Technol. 2016 Dec;53(12):4298-307. doi: 10.1007/s13197- 016-2428-0. [CROSSREF]

    25. Singh BP, Vij S, Hati S. Functional significance of bioactive peptides derived from soybean. Peptides. 2014 Apr;54:171-9. doi: 10.1016/j.peptides.2014.01.022. [CROSSREF]

    26. Nair SS, Kavrekar V, Mishra A. In vitro studies on alpha amylase and alpha glucosidase inhibitory activities of selected plant extracts. Eur J Exp Biol. 2013;3(1):128-32.

    27. Rebello CJ, Greenway FL, Finley JV. A review of the nutritional value of legumes and their effects on obesity and its related co-morbidities. Obes Rev. 2014 May;15(5):392-407. doi: 10.1111/obr.12144. [CROSSREF]

    28. Sreelatha S, Jeyachitra A, Padma PR. Antiproliferation and induction of apoptosis by Moringa Oleifera leaf extract on human cancer cells. Food Chem Toxicol. 2011 Jun;49(6):1270-5. doi: 10.1016/j.fct.2011.03.006. [CROSSREF]

    29. Cáceres A, Girón LM, Alvarado SR, Torres MF. Screening of antimicrobial activity of plants popularly used in Guatemala for the treatment dermatomucosal diseases. J Ethnopharmacol. 1987 Aug;20(3):223-37. doi: 10.1016/0378- 8741(87)90050-x. [CROSSREF]

    30. Guevara AP, Vargas C, Sakurai H, Fujiwara Y, Hashimoto K, Maoka T, et al. An antittumor promoter from Moringa Oleifera Lam. Mutat Res. 1999 Apr;440(2):181-8. doi: 10.1016/s1383-5718[99]00025-X. [CROSSREF]

    31. Costa-Lotufo LV, Khan MT, Ather A, Wilke DV, Jimenez PC, Pessoa C, et al. Studies of the anticancer potential of plants used in Bangladeshi folk medicine. J Ethnopharmacol. 2005 May 13;99(1):21-30. doi: 10.1016/j.jep.2005.01.041. [CROSSREF]

    32. Lee L, Rodriguez J, Tsukiyama T. Chromatin remodeling factors Isw2 and Ino80 regulate checkpoint activity and chromatin structure in S phase. Genetics. 2015 Apr;199(4):1077-91. doi: 10.1534/genetics.115.174730. [CROSSREF]

    33. Sanchez-Machado DI, Nuñez-Gastelum JA, Reyes-Moreno C, Ramírez-Wong B, López-Cervantes J. Nutritional quality of edible parts of Moringa oleifera. Food Anal Method. 2010;3:175-80. doi: 10.1007/s12161-009-9106z. [CROSSREF]

    34. Mirzaie S, Zirak-Khattab F, Hosseini SA, Donyaei-Darian H. Effects of dietary Spirulina on antioxidant status, lipid profile, immune response and performance characteristics of broiler chickens reared under high ambient temperature. Asian-Australas J Anim Sci. 2018 Apr;31(4):556-63. doi: 10.5713/ajas.17.0483. [CROSSREF]

    35. Hidalgo-Lucas S, Rozan P, Guérin-Deremaux L, Baert B, Violle N, Saniez-Degrave MH, et al. Benefits of Preventive Administration of Chlorella sp. on Visceral Pain and Cystitis Induced by a Single Administration of Cyclophosphamide in Female Wistar Rat. J Med Food. 2016 May;19(5):450-6. doi: 10.1089/jmf.2015.0077. [CROSSREF]

    36. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365.39. [CROSSREF]

    37. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A; On behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual [3rd Edition]. Published by: European Organisation for Research and Treatment of Cancer, Brussels; 2001. [CROSSREF]

    38. Berat S, Radulovic S. Trends in use of and attitudes held towards alternative and complementary medicine among patients treated in a Department of Medical Oncology in Serbia. A several-years apart time survey study. J BUON. 2014 Apr-Jun;19(2):535-9.

    39. Gnanaselvan S, Yadav SA, Manoharan SP, Pandiyan B. Uncovering the anticancer potential of phytomedicine and polyherbal's synergism against cancer – A review. Biointerface Research. 2023;13(4):356. doi: 10.33263/ BRIAC134.356. [CROSSREF]

    40. Nikolic I, Smiljenic D, Kukic B, Bogdanovic B, Petrovic T, Ivkovic-Kapicl T, et al. Application of alternative medicine in gastrointestinal cancer patients. Vojnosanit Pregl. 2012;69(11):947-50. [CROSSREF]

    41. Luketina-Šunjka M, Rančić N, Subotić S, Jakovljević M. Complementary and alternative medicine in Serbia: A literature review. Acta Medica Medianae. 2020;59(3):98-104. doi:10.5633/amm.2020.0313. [CROSSREF]

    42. Choudhari AS, Mandave PC, Deshpande M, Ranjekar P, Prakash O. Phytochemicals in cancer treatment: From preclinical studies to clinical practice. Front Pharmacol. 2020 Jan;10:1614. doi: 10.3389/fphar.2019.01614. [CROSSREF]

    43. Battisti NML, Reed MWR, Herbert E, Morgan JL, Collins KA, Ward SE, et al. Bridging the age gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer. Eur J Cancer. 2021 Feb;144:269- 80. doi: 10.1016/j.ejca.2020.11.022. [CROSSREF]

    44. Laskar YB, Lourembam RM, Mazumder PB. Herbal remedies for breast cancer prevention and treatment. In: Hassan BAR, editor. Medicinal Plants - Use in Prevention and Treatment of Diseases. IntechOpen; 2020. doi: 10.5772/ intechopen.89669. [CROSSREF]

    45. Caesar LK, Cech NB. Synergy and antagonism in natural product extracts: when 1+1 does not equal 2. Nat Prod Rep. 2019 Jun;36(6):869-88. doi: 10.1039/c9np00011a. [CROSSREF]

    46. Abbas Z, Manoharan AL, Jagadeesan G, Nataraj G, Muniyandi K, Sathyanarayanan S, et al. Evaluation of an edible polyherbal formulation against urinary tract infection pathogens, its antioxidant and anti-inflammatory potential. Biocatal Agric Biotechnol. 2021;35. doi: 10.1016/j. bcab.2021.102104. [CROSSREF]

    47. Roy A. Plumbagin: A potential anti-cancer compound. Mini Rev Med Chem. 2021;21(6):731-7. doi: 10.2174/1389557520666201116144421. [CROSSREF]


REFERENCES

1. De la Cruz M, Bandiano J. Libellus de medicinalibus Indorum herbis: manuscrito azteca de 1552. 2. ed. México, D.F: Fondo de Cultura Económica: Instituto Mexicano del Seguro Social; 1991. 2 p.

2. Figueroa-Hernández JL, Céspedes-Cortés, Figueroa-Espitia JL. Flora Silvestre presente en un nuevo asentamiento urbano en la Delegación de Xochimilco en México, D.F. In: XXVI Congreso Nacional de Farmacología; 2004 Мay 25-28; Morelia, Michoacán, Mexico.

3. Greenlee H, Balneaves LG, Carlson LE, Cohen M, Deng G, Hershman D, et al. Society for Integrative Oncology. Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. J Natl Cancer Inst Monogr. 2014 Nov;2014(50):346-58. doi: 10.1093/jncimonographs/lgu041. [CROSSREF]

4. Lianes Barragan P, Fernández Bruno M, Martínez Peralta S. Medicina Integrativa en el paciente oncológico. In: Escobar Álvarez Y, Blasco Cordellat A, Espinosa Arranz J, De las Peñas Bataller R, Del Mar Muñoz Sánchez M, Virizuela Echaburu JA, et al., editors. Manual de Cuidados Continuos de SEOM, 2A Edición. Madrid: Sociedad Española de Oncología Médica (SEOM); 2014. p. 489-97.

5. Bañuelos MR. Medicina integrativa en el paciente oncológico: Estrategia de la Organización Mundial de la Salud y estado actual. Revista Medica de Homeopatia. 2013;6(3):136-40. doi: 10.1016/j.homeo.2013.10.001. [CROSSREF]

6. Shike M, Brennan MF. Supportive care of the cancer patient. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice in Oncology. Philadelphia, PA: J.B. Lippincott; 1989. P. 2029-44.

7. Deng GE, Frenkel M, Cohen L, Cassileth BR, Abrams DI, Capodice JL, et al. Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals. J Soc Integr Oncol. 2009;7(3):85-120. [HTTP]

8. Thinking About Complementary and Alternative Medicine: A Guide for People with Cancer. National Institutes of Health.

9. Heber D, Blackburn GL, Go VLW. Introduction: The principles of nutrition oncology. In: Heber D, Blackburn GL, Go VLW. Nutritional Oncology. San Diego, CA: Academic Press; 1999. p. 1-10.

10. Lemus Rodríguez Z, García Pérez ME, Batista Duharte A, De la Guardia Peña O, Alfonso Castillo A. La tableta de anamú: un medicamento herbario inmunoestimulante. MEDISAN. 2004;8(3).

11. García Pérez ME, Lemus Rodríguez Z, Hung Arbelo M., Vistel Vigo M. Influence of polyvinylpyrrolidone, microcrystalline cellulose and colloidal silicon dioxide on technological characteristics of a high-dose Petiveria alliacea tablet. Drug Dev. Ind. Pharm. 2017 Dec; 43(12):2011-5. doi: 10.1080/03639045.2017.1359621. [CROSSREF]

12. Jovicevic L, Troiani MP, Capezzone de Joannon A, Saso L, Mazzanti G, Rossi V. In vitro antiproliferative activity of Petiveria alliacea L. on several t tumor cell lines. Pharmacol Res. 1993;27(S1):105-6. doi: https://doi.org/10.1006/phrs.1993.1087. [CROSSREF]

13. Marini S, Jovicevic L, Milanese C, Giardina B, Leone MG. Effects of Petiveria alliacea L. on cytokine production and natural killer cell activity. Pharmacol Res. 1993;27(S1):107-8. doi: https://doi.org/10.1006/phrs.1993.1088. [CROSSREF]

14. Williams LAD, The TL, Gardner MT, Fletcher CK, Naravane A, Gibbs N, et al. Immunomodulatory activities of Petiveria alliacea L. Phytother Res. 1997;11(3):251- 3. doi: 10.1002/(sici)1099-1573(199705)11:33.0.co;2-b. [CROSSREF]

15. Kubec R, Musah R. Cysteine sulfoxide derivatives in Petiveria alliacea. Phytochemistry. 2001 Nov;58(6):981-5. doi: 10.1016/s0031-9422(01)00304-1. [CROSSREF]

16. Queiroz ML. Cytokine profile and natural killer cell activity in Listeria monocytogenes infected mice treated orally with Petiveria alliacea extract. Immunopharmacol Immunotoxicol. 2000 Aug;22(3):501-18. doi: 10.3109/08923970009026008. [CROSSREF]

17. Urueña C, Cifuentes C, Castañeda D, Arango A, Kaur P, Asea A, et al. Petiveria alliacea extracts multiple mechanisms to inhibit growth of human and mouse ttumoral cells. BMC Complement Altern Med. 2008;8(60). doi: 10.1186/1472-6882-8-60. [CROSSREF]

18. Anwar F, Latif S, Ashraf M, Gilani AH. Moringa Oleifera: a food plant with multiple medicinal uses. Phytother Res. 2007 Jan;21(1):17-25. doi: 10.1002/ ptr.2023. [CROSSREF]

19. Kasolo JN, Bimenya GS, Ojok L, Ochieng J, Ogwal-Okeng JW. Phytochemicals and uses of Moringa Oleifera leaves in Ugandan rural communities. J Med Plants Res. 2010;4(9):753-7.

20. Vats S, Grupta T. Evaluation of bioactive compounds and antioxidant potential of hydroethanolic extract of Moringa Oleifera Lam from Rajasthan, India. Physiol Mol Biol Plants. 2017 Jan;23(1):239-48. doi: 10.1007/s12298- 016-0407-6. [CROSSREF]

21. Mehta S, Rai PK, Rai NK, Rai AK, Bicanic D, Watal G. Role of spectral studies in detection of antibacterial phytoelements and phytochemicals of Moringa Oleifera. Food Biophys. 2011 Jun;6(4):497-502. doi: 10.1007/s11483-011-9231-2. [CROSSREF]

22. Jung IL. Soluble extract from Moringa Oleifera leaves with a new anticancer activity. PLoS One. 2014 Apr;9(4):e95492. doi:10.1371/journal.pone.0095492. [CROSSREF]

23. Kitts DD, Weiler K. Bioactive proteins and peptides from food sources. Applications of bioprocesses used in isolation and recovery. Curr Pharm Des. 2003;9(16):1309-23. doi: 10.2174/1381612033454883. [CROSSREF]

24. Lopez-Sanchez J, Ponce-Alquicira E, Pedroza-Islas R, de la Peña Diaz A, Soriano-Santos J. Effects of heat and pH treatments and in vitro digestion on the biological activity of protein hydrolysates of Amaranthus hypochondriacus L. grain. J Food Sci Technol. 2016 Dec;53(12):4298-307. doi: 10.1007/s13197- 016-2428-0. [CROSSREF]

25. Singh BP, Vij S, Hati S. Functional significance of bioactive peptides derived from soybean. Peptides. 2014 Apr;54:171-9. doi: 10.1016/j.peptides.2014.01.022. [CROSSREF]

26. Nair SS, Kavrekar V, Mishra A. In vitro studies on alpha amylase and alpha glucosidase inhibitory activities of selected plant extracts. Eur J Exp Biol. 2013;3(1):128-32.

27. Rebello CJ, Greenway FL, Finley JV. A review of the nutritional value of legumes and their effects on obesity and its related co-morbidities. Obes Rev. 2014 May;15(5):392-407. doi: 10.1111/obr.12144. [CROSSREF]

28. Sreelatha S, Jeyachitra A, Padma PR. Antiproliferation and induction of apoptosis by Moringa Oleifera leaf extract on human cancer cells. Food Chem Toxicol. 2011 Jun;49(6):1270-5. doi: 10.1016/j.fct.2011.03.006. [CROSSREF]

29. Cáceres A, Girón LM, Alvarado SR, Torres MF. Screening of antimicrobial activity of plants popularly used in Guatemala for the treatment dermatomucosal diseases. J Ethnopharmacol. 1987 Aug;20(3):223-37. doi: 10.1016/0378- 8741(87)90050-x. [CROSSREF]

30. Guevara AP, Vargas C, Sakurai H, Fujiwara Y, Hashimoto K, Maoka T, et al. An antittumor promoter from Moringa Oleifera Lam. Mutat Res. 1999 Apr;440(2):181-8. doi: 10.1016/s1383-5718[99]00025-X. [CROSSREF]

31. Costa-Lotufo LV, Khan MT, Ather A, Wilke DV, Jimenez PC, Pessoa C, et al. Studies of the anticancer potential of plants used in Bangladeshi folk medicine. J Ethnopharmacol. 2005 May 13;99(1):21-30. doi: 10.1016/j.jep.2005.01.041. [CROSSREF]

32. Lee L, Rodriguez J, Tsukiyama T. Chromatin remodeling factors Isw2 and Ino80 regulate checkpoint activity and chromatin structure in S phase. Genetics. 2015 Apr;199(4):1077-91. doi: 10.1534/genetics.115.174730. [CROSSREF]

33. Sanchez-Machado DI, Nuñez-Gastelum JA, Reyes-Moreno C, Ramírez-Wong B, López-Cervantes J. Nutritional quality of edible parts of Moringa oleifera. Food Anal Method. 2010;3:175-80. doi: 10.1007/s12161-009-9106z. [CROSSREF]

34. Mirzaie S, Zirak-Khattab F, Hosseini SA, Donyaei-Darian H. Effects of dietary Spirulina on antioxidant status, lipid profile, immune response and performance characteristics of broiler chickens reared under high ambient temperature. Asian-Australas J Anim Sci. 2018 Apr;31(4):556-63. doi: 10.5713/ajas.17.0483. [CROSSREF]

35. Hidalgo-Lucas S, Rozan P, Guérin-Deremaux L, Baert B, Violle N, Saniez-Degrave MH, et al. Benefits of Preventive Administration of Chlorella sp. on Visceral Pain and Cystitis Induced by a Single Administration of Cyclophosphamide in Female Wistar Rat. J Med Food. 2016 May;19(5):450-6. doi: 10.1089/jmf.2015.0077. [CROSSREF]

36. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365.39. [CROSSREF]

37. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A; On behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual [3rd Edition]. Published by: European Organisation for Research and Treatment of Cancer, Brussels; 2001. [CROSSREF]

38. Berat S, Radulovic S. Trends in use of and attitudes held towards alternative and complementary medicine among patients treated in a Department of Medical Oncology in Serbia. A several-years apart time survey study. J BUON. 2014 Apr-Jun;19(2):535-9.

39. Gnanaselvan S, Yadav SA, Manoharan SP, Pandiyan B. Uncovering the anticancer potential of phytomedicine and polyherbal's synergism against cancer – A review. Biointerface Research. 2023;13(4):356. doi: 10.33263/ BRIAC134.356. [CROSSREF]

40. Nikolic I, Smiljenic D, Kukic B, Bogdanovic B, Petrovic T, Ivkovic-Kapicl T, et al. Application of alternative medicine in gastrointestinal cancer patients. Vojnosanit Pregl. 2012;69(11):947-50. [CROSSREF]

41. Luketina-Šunjka M, Rančić N, Subotić S, Jakovljević M. Complementary and alternative medicine in Serbia: A literature review. Acta Medica Medianae. 2020;59(3):98-104. doi:10.5633/amm.2020.0313. [CROSSREF]

42. Choudhari AS, Mandave PC, Deshpande M, Ranjekar P, Prakash O. Phytochemicals in cancer treatment: From preclinical studies to clinical practice. Front Pharmacol. 2020 Jan;10:1614. doi: 10.3389/fphar.2019.01614. [CROSSREF]

43. Battisti NML, Reed MWR, Herbert E, Morgan JL, Collins KA, Ward SE, et al. Bridging the age gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer. Eur J Cancer. 2021 Feb;144:269- 80. doi: 10.1016/j.ejca.2020.11.022. [CROSSREF]

44. Laskar YB, Lourembam RM, Mazumder PB. Herbal remedies for breast cancer prevention and treatment. In: Hassan BAR, editor. Medicinal Plants - Use in Prevention and Treatment of Diseases. IntechOpen; 2020. doi: 10.5772/ intechopen.89669. [CROSSREF]

45. Caesar LK, Cech NB. Synergy and antagonism in natural product extracts: when 1+1 does not equal 2. Nat Prod Rep. 2019 Jun;36(6):869-88. doi: 10.1039/c9np00011a. [CROSSREF]

46. Abbas Z, Manoharan AL, Jagadeesan G, Nataraj G, Muniyandi K, Sathyanarayanan S, et al. Evaluation of an edible polyherbal formulation against urinary tract infection pathogens, its antioxidant and anti-inflammatory potential. Biocatal Agric Biotechnol. 2021;35. doi: 10.1016/j. bcab.2021.102104. [CROSSREF]

47. Roy A. Plumbagin: A potential anti-cancer compound. Mini Rev Med Chem. 2021;21(6):731-7. doi: 10.2174/1389557520666201116144421. [CROSSREF]

1. De la Cruz M, Bandiano J. Libellus de medicinalibus Indorum herbis: manuscrito azteca de 1552. 2. ed. México, D.F: Fondo de Cultura Económica: Instituto Mexicano del Seguro Social; 1991. 2 p.

2. Figueroa-Hernández JL, Céspedes-Cortés, Figueroa-Espitia JL. Flora Silvestre presente en un nuevo asentamiento urbano en la Delegación de Xochimilco en México, D.F. In: XXVI Congreso Nacional de Farmacología; 2004 Мay 25-28; Morelia, Michoacán, Mexico.

3. Greenlee H, Balneaves LG, Carlson LE, Cohen M, Deng G, Hershman D, et al. Society for Integrative Oncology. Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. J Natl Cancer Inst Monogr. 2014 Nov;2014(50):346-58. doi: 10.1093/jncimonographs/lgu041. [CROSSREF]

4. Lianes Barragan P, Fernández Bruno M, Martínez Peralta S. Medicina Integrativa en el paciente oncológico. In: Escobar Álvarez Y, Blasco Cordellat A, Espinosa Arranz J, De las Peñas Bataller R, Del Mar Muñoz Sánchez M, Virizuela Echaburu JA, et al., editors. Manual de Cuidados Continuos de SEOM, 2A Edición. Madrid: Sociedad Española de Oncología Médica (SEOM); 2014. p. 489-97.

5. Bañuelos MR. Medicina integrativa en el paciente oncológico: Estrategia de la Organización Mundial de la Salud y estado actual. Revista Medica de Homeopatia. 2013;6(3):136-40. doi: 10.1016/j.homeo.2013.10.001. [CROSSREF]

6. Shike M, Brennan MF. Supportive care of the cancer patient. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice in Oncology. Philadelphia, PA: J.B. Lippincott; 1989. P. 2029-44.

7. Deng GE, Frenkel M, Cohen L, Cassileth BR, Abrams DI, Capodice JL, et al. Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals. J Soc Integr Oncol. 2009;7(3):85-120. [HTTP]

8. Thinking About Complementary and Alternative Medicine: A Guide for People with Cancer. National Institutes of Health.

9. Heber D, Blackburn GL, Go VLW. Introduction: The principles of nutrition oncology. In: Heber D, Blackburn GL, Go VLW. Nutritional Oncology. San Diego, CA: Academic Press; 1999. p. 1-10.

10. Lemus Rodríguez Z, García Pérez ME, Batista Duharte A, De la Guardia Peña O, Alfonso Castillo A. La tableta de anamú: un medicamento herbario inmunoestimulante. MEDISAN. 2004;8(3).

11. García Pérez ME, Lemus Rodríguez Z, Hung Arbelo M., Vistel Vigo M. Influence of polyvinylpyrrolidone, microcrystalline cellulose and colloidal silicon dioxide on technological characteristics of a high-dose Petiveria alliacea tablet. Drug Dev. Ind. Pharm. 2017 Dec; 43(12):2011-5. doi: 10.1080/03639045.2017.1359621. [CROSSREF]

12. Jovicevic L, Troiani MP, Capezzone de Joannon A, Saso L, Mazzanti G, Rossi V. In vitro antiproliferative activity of Petiveria alliacea L. on several t tumor cell lines. Pharmacol Res. 1993;27(S1):105-6. doi: https://doi.org/10.1006/phrs.1993.1087. [CROSSREF]

13. Marini S, Jovicevic L, Milanese C, Giardina B, Leone MG. Effects of Petiveria alliacea L. on cytokine production and natural killer cell activity. Pharmacol Res. 1993;27(S1):107-8. doi: https://doi.org/10.1006/phrs.1993.1088. [CROSSREF]

14. Williams LAD, The TL, Gardner MT, Fletcher CK, Naravane A, Gibbs N, et al. Immunomodulatory activities of Petiveria alliacea L. Phytother Res. 1997;11(3):251- 3. doi: 10.1002/(sici)1099-1573(199705)11:33.0.co;2-b. [CROSSREF]

15. Kubec R, Musah R. Cysteine sulfoxide derivatives in Petiveria alliacea. Phytochemistry. 2001 Nov;58(6):981-5. doi: 10.1016/s0031-9422(01)00304-1. [CROSSREF]

16. Queiroz ML. Cytokine profile and natural killer cell activity in Listeria monocytogenes infected mice treated orally with Petiveria alliacea extract. Immunopharmacol Immunotoxicol. 2000 Aug;22(3):501-18. doi: 10.3109/08923970009026008. [CROSSREF]

17. Urueña C, Cifuentes C, Castañeda D, Arango A, Kaur P, Asea A, et al. Petiveria alliacea extracts multiple mechanisms to inhibit growth of human and mouse ttumoral cells. BMC Complement Altern Med. 2008;8(60). doi: 10.1186/1472-6882-8-60. [CROSSREF]

18. Anwar F, Latif S, Ashraf M, Gilani AH. Moringa Oleifera: a food plant with multiple medicinal uses. Phytother Res. 2007 Jan;21(1):17-25. doi: 10.1002/ ptr.2023. [CROSSREF]

19. Kasolo JN, Bimenya GS, Ojok L, Ochieng J, Ogwal-Okeng JW. Phytochemicals and uses of Moringa Oleifera leaves in Ugandan rural communities. J Med Plants Res. 2010;4(9):753-7.

20. Vats S, Grupta T. Evaluation of bioactive compounds and antioxidant potential of hydroethanolic extract of Moringa Oleifera Lam from Rajasthan, India. Physiol Mol Biol Plants. 2017 Jan;23(1):239-48. doi: 10.1007/s12298- 016-0407-6. [CROSSREF]

21. Mehta S, Rai PK, Rai NK, Rai AK, Bicanic D, Watal G. Role of spectral studies in detection of antibacterial phytoelements and phytochemicals of Moringa Oleifera. Food Biophys. 2011 Jun;6(4):497-502. doi: 10.1007/s11483-011-9231-2. [CROSSREF]

22. Jung IL. Soluble extract from Moringa Oleifera leaves with a new anticancer activity. PLoS One. 2014 Apr;9(4):e95492. doi:10.1371/journal.pone.0095492. [CROSSREF]

23. Kitts DD, Weiler K. Bioactive proteins and peptides from food sources. Applications of bioprocesses used in isolation and recovery. Curr Pharm Des. 2003;9(16):1309-23. doi: 10.2174/1381612033454883. [CROSSREF]

24. Lopez-Sanchez J, Ponce-Alquicira E, Pedroza-Islas R, de la Peña Diaz A, Soriano-Santos J. Effects of heat and pH treatments and in vitro digestion on the biological activity of protein hydrolysates of Amaranthus hypochondriacus L. grain. J Food Sci Technol. 2016 Dec;53(12):4298-307. doi: 10.1007/s13197- 016-2428-0. [CROSSREF]

25. Singh BP, Vij S, Hati S. Functional significance of bioactive peptides derived from soybean. Peptides. 2014 Apr;54:171-9. doi: 10.1016/j.peptides.2014.01.022. [CROSSREF]

26. Nair SS, Kavrekar V, Mishra A. In vitro studies on alpha amylase and alpha glucosidase inhibitory activities of selected plant extracts. Eur J Exp Biol. 2013;3(1):128-32.

27. Rebello CJ, Greenway FL, Finley JV. A review of the nutritional value of legumes and their effects on obesity and its related co-morbidities. Obes Rev. 2014 May;15(5):392-407. doi: 10.1111/obr.12144. [CROSSREF]

28. Sreelatha S, Jeyachitra A, Padma PR. Antiproliferation and induction of apoptosis by Moringa Oleifera leaf extract on human cancer cells. Food Chem Toxicol. 2011 Jun;49(6):1270-5. doi: 10.1016/j.fct.2011.03.006. [CROSSREF]

29. Cáceres A, Girón LM, Alvarado SR, Torres MF. Screening of antimicrobial activity of plants popularly used in Guatemala for the treatment dermatomucosal diseases. J Ethnopharmacol. 1987 Aug;20(3):223-37. doi: 10.1016/0378- 8741(87)90050-x. [CROSSREF]

30. Guevara AP, Vargas C, Sakurai H, Fujiwara Y, Hashimoto K, Maoka T, et al. An antittumor promoter from Moringa Oleifera Lam. Mutat Res. 1999 Apr;440(2):181-8. doi: 10.1016/s1383-5718[99]00025-X. [CROSSREF]

31. Costa-Lotufo LV, Khan MT, Ather A, Wilke DV, Jimenez PC, Pessoa C, et al. Studies of the anticancer potential of plants used in Bangladeshi folk medicine. J Ethnopharmacol. 2005 May 13;99(1):21-30. doi: 10.1016/j.jep.2005.01.041. [CROSSREF]

32. Lee L, Rodriguez J, Tsukiyama T. Chromatin remodeling factors Isw2 and Ino80 regulate checkpoint activity and chromatin structure in S phase. Genetics. 2015 Apr;199(4):1077-91. doi: 10.1534/genetics.115.174730. [CROSSREF]

33. Sanchez-Machado DI, Nuñez-Gastelum JA, Reyes-Moreno C, Ramírez-Wong B, López-Cervantes J. Nutritional quality of edible parts of Moringa oleifera. Food Anal Method. 2010;3:175-80. doi: 10.1007/s12161-009-9106z. [CROSSREF]

34. Mirzaie S, Zirak-Khattab F, Hosseini SA, Donyaei-Darian H. Effects of dietary Spirulina on antioxidant status, lipid profile, immune response and performance characteristics of broiler chickens reared under high ambient temperature. Asian-Australas J Anim Sci. 2018 Apr;31(4):556-63. doi: 10.5713/ajas.17.0483. [CROSSREF]

35. Hidalgo-Lucas S, Rozan P, Guérin-Deremaux L, Baert B, Violle N, Saniez-Degrave MH, et al. Benefits of Preventive Administration of Chlorella sp. on Visceral Pain and Cystitis Induced by a Single Administration of Cyclophosphamide in Female Wistar Rat. J Med Food. 2016 May;19(5):450-6. doi: 10.1089/jmf.2015.0077. [CROSSREF]

36. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365.39. [CROSSREF]

37. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A; On behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual [3rd Edition]. Published by: European Organisation for Research and Treatment of Cancer, Brussels; 2001. [CROSSREF]

38. Berat S, Radulovic S. Trends in use of and attitudes held towards alternative and complementary medicine among patients treated in a Department of Medical Oncology in Serbia. A several-years apart time survey study. J BUON. 2014 Apr-Jun;19(2):535-9.

39. Gnanaselvan S, Yadav SA, Manoharan SP, Pandiyan B. Uncovering the anticancer potential of phytomedicine and polyherbal's synergism against cancer – A review. Biointerface Research. 2023;13(4):356. doi: 10.33263/ BRIAC134.356. [CROSSREF]

40. Nikolic I, Smiljenic D, Kukic B, Bogdanovic B, Petrovic T, Ivkovic-Kapicl T, et al. Application of alternative medicine in gastrointestinal cancer patients. Vojnosanit Pregl. 2012;69(11):947-50. [CROSSREF]

41. Luketina-Šunjka M, Rančić N, Subotić S, Jakovljević M. Complementary and alternative medicine in Serbia: A literature review. Acta Medica Medianae. 2020;59(3):98-104. doi:10.5633/amm.2020.0313. [CROSSREF]

42. Choudhari AS, Mandave PC, Deshpande M, Ranjekar P, Prakash O. Phytochemicals in cancer treatment: From preclinical studies to clinical practice. Front Pharmacol. 2020 Jan;10:1614. doi: 10.3389/fphar.2019.01614. [CROSSREF]

43. Battisti NML, Reed MWR, Herbert E, Morgan JL, Collins KA, Ward SE, et al. Bridging the age gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer. Eur J Cancer. 2021 Feb;144:269- 80. doi: 10.1016/j.ejca.2020.11.022. [CROSSREF]

44. Laskar YB, Lourembam RM, Mazumder PB. Herbal remedies for breast cancer prevention and treatment. In: Hassan BAR, editor. Medicinal Plants - Use in Prevention and Treatment of Diseases. IntechOpen; 2020. doi: 10.5772/ intechopen.89669. [CROSSREF]

45. Caesar LK, Cech NB. Synergy and antagonism in natural product extracts: when 1+1 does not equal 2. Nat Prod Rep. 2019 Jun;36(6):869-88. doi: 10.1039/c9np00011a. [CROSSREF]

46. Abbas Z, Manoharan AL, Jagadeesan G, Nataraj G, Muniyandi K, Sathyanarayanan S, et al. Evaluation of an edible polyherbal formulation against urinary tract infection pathogens, its antioxidant and anti-inflammatory potential. Biocatal Agric Biotechnol. 2021;35. doi: 10.1016/j. bcab.2021.102104. [CROSSREF]

47. Roy A. Plumbagin: A potential anti-cancer compound. Mini Rev Med Chem. 2021;21(6):731-7. doi: 10.2174/1389557520666201116144421. [CROSSREF]


© All rights reserved. Medical Chamber of Serbia.

To top